Cancer
Cancer Ongoing 2020 Michigan: Maria Pappas (248) 553-0606

S1914

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

Trial overview

Disease
Lung cancer treatment and diagnosis
Topic
S1914
Description
Primary Objective:To compare overall survival (OS) in patients with inoperable, early stage non-small cell lung cancer (NSCLC) randomized to stereotactic body radiation therapy (SBRT) with or without atezolizumab.Patient Population:Patients must have histologically or cytologically proven Stage I-IIA or limited T3N0M0 non-small cell lung cancer (NSCLC) without radiographic evidence of nodal or distant involvement (N0M0). Patients may have T3 disease with the exclusion of multifocal tumors and pericardial involvement.
Physicians

Dr. Alvaro A. Martinez

MD, FACR, FABS, FASTRO

Radiation Oncologist

Works at 5 centers.

Dr. Frank A. Vicini

MD, FACR, FASTRO

Radiation oncologist

Works at 3 centers.

Dr. Larry L. Kestin

MD, FACR

Radiation Oncologist

Works at 3 centers.

Dr. Thomas Boike

MD

Radiation Oncologist

Works at 3 centers.

Dr. Michael I. Ghilezan

MD, PhD

Radiation Oncologist

Works at 4 centers.

Dr. John Vito Antonucci

MD

Radiation Oncologist

Works at 4 centers.